Experimental drug offers hope for leukemia patients out of options
NCT ID NCT06969430
Summary
This early-stage trial is testing a new drug called Debio 1562M for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The study aims to find a safe dose and see if the drug can reduce or eliminate leukemia cells. Participants will receive the experimental drug to evaluate both safety and effectiveness against this aggressive blood cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
City of Hope Comprehensive Cancer Center
RECRUITINGDuarte, California, 91010, United States
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Moffitt Cancer Center and Research Institute Hospital
RECRUITINGTampa, Florida, 33612-9416, United States
-
Roswell Park Comprehensive Cancer Center
NOT_YET_RECRUITINGBuffalo, New York, 14203, United States
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
-
The Ohio Sate University
RECRUITINGColumbus, Ohio, 43210, United States
-
University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.